SOPHiA GENETICS, Complete Genomics Unite for Precision Medicine

Complete Genomics, a number one innovator in genomic sequencing, right this moment introduced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a worldwide chief in AI-driven precision medication, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM on Complete Genomics’ DNBSEQ-T1+ sequencing platform. The firms purpose to broaden entry to precision oncology testing by providing the best-in-class liquid biopsy and stable tumor functions to prospects globally. The announcement was constructed from the Association for Molecular Pathology (AMP) Annual Meeting in Boston.

The collaboration integrates SOPHiA GENETICS’ superior, AI-powered functions MSK-IMPACT® and MSK-ACCESS® powered by SOPHiA DDM, developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), with Complete Genomics’ newly launched DNBSEQ-T1+ sequencing platform. Together, Complete Genomics and SOPHiA GENETICS will present an built-in, sample-to-report workflow for laboratories, marking a big enlargement of their partnership into the precision oncology analysis market.

“Pairing MSK-IMPACT® and MSK-ACCESS® powered with SOPHiA DDM with our DNBSEQ-T1+ platform creates a robust and accessible resolution for laboratories trying to scale high-quality most cancers genomic profiling,” mentioned Rob Tarbox, vp of product and advertising and marketing at Complete Genomics. “By combining MSK’s rigorously validated assays, SOPHiA GENETICS’ sturdy analytics, and our sequencing know-how, we’re enabling decentralized labs to ship sooner, extra correct, and extra inexpensive insights to clinicians and researchers.”

“This collaboration underscores SOPHiA GENETICS’ dedication to broadening entry to data-driven medication,” mentioned Ross Muken, President, SOPHiA GENETICS. “Partnering with Complete Genomics to streamline use of MSK-IMPACT® and MSK-ACCESS® powered with SOPHiA DDM on the DNBSEQ-T1+ platform allows extra laboratories world wide to undertake precision oncology by scalable, end-to-end genomic options.”

The DNBSEQ-T1+, powered by proprietary DNBSEQ know-how, delivers Q40-level accuracy, optimized throughput from 500 million to 2 billion reads per circulation cell. Each circulation cell is ready to be run independently, with a 24-hour paired-end 150bp run time, providing laboratories an economical and extremely versatile sequencing resolution. At most throughput, every T1+ circulation cell can run as much as 60 tumor-normal pattern pairs for tissue, as much as 16 tumor-normal pattern pairs for liquid biopsy.

SOPHiA DDM is a technology-agnostic analytics platform that leverages AI to compute, standardize, and analyze healthcare information. Joint analysis of MSK-IMPACT® and MSK-ACCESS® on the DNBSEQ-T1+ platform demonstrated extremely concordant variant calls and allele frequencies in contrast with equal sequencing techniques, whereas attaining decrease background noise, diminished turnaround time, and seamless compatibility with present SOPHiA DDM workflows.

This new providing gives scientific laboratories, most cancers facilities, and drug builders with a high-performance, cost-efficient path to implementing complete genomic profiling for precision oncology analysis.

The put up SOPHiA GENETICS, Complete Genomics Unite for Precision Medicine first appeared on AI-Tech Park.